A Randomised, Controlled, Double-Blind Study of the Immunogenicity and Safety of PEDIACEL, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed) Compared To Infanrix-IPV+Hib When Both Vaccines Are Given to Infants Using a Three Dose Immunisation Schedule ('Nordic Schedule' 3-5-12 Months).

Trial Profile

A Randomised, Controlled, Double-Blind Study of the Immunogenicity and Safety of PEDIACEL, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed) Compared To Infanrix-IPV+Hib When Both Vaccines Are Given to Infants Using a Three Dose Immunisation Schedule ('Nordic Schedule' 3-5-12 Months).

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine (Primary)
  • Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Feb 2010 Official Title amended, actual patient number added as 807 as reported by ClinicalTrials.gov.
    • 26 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Planned end date (Aug 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top